Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial
ContributorsIglesias, Juan Fernando; Muller, Olivier; Heg, Dik; Roffi, Marco; Kurz, David J; Moarof, Igal; Weilenmann, Daniel; Kaiser, Christoph; Tapponnier, Maxime; Stortecky, Stefan; Losdat, Sylvain; Eeckhout, Eric; Valgimigli, Marco; Odutayo, Ayodele; Zwahlen, Marcel; Jüni, Peter; Windecker, Stephan; Pilgrim, Thomas
Published inThe Lancet, vol. 394, no. 10205, p. 1243-1253
Publication date2019-10-05
First online date2019-09-02
Abstract
Keywords
- Absorbable Implants
- Blood Vessel Prosthesis
- Drug-Eluting Stents
- Everolimus / therapeutic use
- Female
- Humans
- Immunosuppressive Agents / therapeutic use
- Male
- Middle Aged
- Percutaneous Coronary Intervention / methods
- Polymers
- ST Elevation Myocardial Infarction / surgery
- Single-Blind Method
- Sirolimus / therapeutic use
Affiliation
Citation (ISO format)
IGLESIAS, Juan Fernando et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. In: The Lancet, 2019, vol. 394, n° 10205, p. 1243–1253. doi: 10.1016/S0140-6736(19)31877-X
Main files (2)
Article (Published version)
Article (Accepted version)
Secondary files (1)
Identifiers
- PID : unige:161097
- DOI : 10.1016/S0140-6736(19)31877-X
- PMID : 31488372
ISSN of the journal0140-6736